Sarepta Therapeutics Inc (NASDAQ:SRPT)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Results 1 - 20 of 55 : 1 2 3 Next »

Recs

1
Member Avatar zzlangerhans (99.84) Submitted: 12/7/2014 11:06:07 PM : Outperform Start Price: $15.45 SRPT Score: -10.71

There's no denying that Sarepta is a cult stock only rivaled by Mannkind. Similarly to Mannkind, Sarepta always seems to overshoot the rational price range in either direction depending on prevailing sentiment, and right now the wind is blowing south. Delays in the eteplirsen NDA submission, the buyout of Prosensa, the deflation of Ebola hype have all exerted downward pressure on Sarepta stock.

What does this situation remind me of most? Mannkind in mid 2012, wallowing in the quagmires after a CRL for Afrezza and looking as though they were about to be crushed by debt. In fact, that was one of the buying opportunities of this decade as the stock rose from 1.7 in 2012 to a high of 10.5 in 2014. I'm not sure that Sarepta has quite the same potential for appreciation, but I like the play when most of the long-term bulls on Twitter have capitulated and the decline in the stock seems to have stabilized. Portefeuille and I have accumulated 1000 shares for our zzporte collaboration with a cost basis of 17.22.

Recs

1
Member Avatar deacon (< 20) Submitted: 10/16/2014 6:50:24 PM : Outperform Start Price: $24.74 SRPT Score: -54.17

EBOLA treatment drug advanced to primate testing showing no adverse side effects

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 10/10/2014 9:35:55 PM : Outperform Start Price: $18.75 SRPT Score: -35.06

Short term burst in stock price due to Ebola panic. This stock should go higher over the next year.

Recs

1
Member Avatar jbwheels69 (55.91) Submitted: 10/1/2014 3:09:23 PM : Outperform Start Price: $21.93 SRPT Score: -43.67

Decent entry point

Recs

1
Member Avatar trizoll (58.17) Submitted: 7/16/2014 9:55:29 PM : Outperform Start Price: $20.50 SRPT Score: -37.57

Will rebound from 144 week study results. The benefit is really compared to the placebo. There is a huge benefit there. I think the drug will get approved in 2015.

Recs

0
Member Avatar MKArch (99.76) Submitted: 7/2/2014 2:30:14 AM : Outperform Start Price: $30.14 SRPT Score: -59.39

Following a guy on Yahoo Finance that sounds like he knows what he's talking about. Yep really that's it. O.K. he made an interesting argument for HART a similar company I have done a little investigating into so I'm taking a flier that he understands this one enough to put it into my CAPS portfolio. Potential multi-bagger a few years out, we shall see.

Recs

0
Member Avatar Redbeagle (32.99) Submitted: 3/17/2014 12:07:55 PM : Outperform Start Price: $27.23 SRPT Score: -60.57

Good drug pipeline

Recs

0
Member Avatar mulledover (79.80) Submitted: 3/15/2014 11:59:06 AM : Outperform Start Price: $27.38 SRPT Score: -61.26

Phase ii results in duchenne prove their capabilities although this will likely take 2-3 years for further trials. However it's their RNA platform that makes this an interesting company for antiviral drugs for infectious diseases

Recs

0
Member Avatar manirg (68.78) Submitted: 1/27/2014 12:41:25 PM : Outperform Start Price: $23.28 SRPT Score: -57.31

Its drug is only the treatment for DMD. FDA is likely to approve it sooner or later. Hugh long term potential.

Recs

0
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $24.65 SRPT Score: -59.73

The only game in town when it comes to Duchenne Muscular Dystophy.

Recs

0
Member Avatar ferrariedgardo (27.91) Submitted: 1/16/2014 6:57:41 PM : Outperform Start Price: $27.37 SRPT Score: -62.14

DMD trial going well

Recs

1
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $32.49 SRPT Score: +82.03

Short. Biopharma. Sells more stock than has revenues. Revs declining too.

Recs

3
Member Avatar EllenBrandtPhD (< 20) Submitted: 8/17/2013 2:58:48 PM : Outperform Start Price: $32.59 SRPT Score: -83.00

This is a terrifying stock, because its moves tend to be so dramatic.

If you calculate its next Big Turn correctly, either on the downside or the upside, you can make out like a bandit.

The technical picture could hardly have been worse prior to Friday's big up day, but there were many hints something was brewing. It came in the form of a key analyst upgrade and a new Propaganda push beginning Friday.

I think it may continue and that the next Big Turn - Propaganda leading Technicals - may be here.

Recs

3
Member Avatar TMFBiologyFool (96.70) Submitted: 7/24/2013 4:31:02 PM : Outperform Start Price: $37.00 SRPT Score: -86.00

Over punished on delay of FDA decision about surrogate endpoint. Should trend back up as we get closer to FDA decision.

Recs

0
Member Avatar SUPERSTOCKS007 (< 20) Submitted: 5/27/2013 1:39:26 PM : Outperform Start Price: $38.75 SRPT Score: -88.56

right drug at the right time

Recs

0
Member Avatar IBDContrarian (23.30) Submitted: 4/6/2013 1:51:34 PM : Underperform Start Price: $37.06 SRPT Score: +96.36

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 99 EB NO EARN

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:34:43 PM : Outperform Start Price: $30.37 SRPT Score: -91.20

SRPT is about to breakout huge to the upside on accelerated approval status by the FDA. Initial projections of a patient population of only 300 is vastly underestimated as it is closer to 6,000.

Recs

0
Member Avatar ravikaza2 (< 20) Submitted: 3/3/2013 7:57:45 PM : Outperform Start Price: $30.37 SRPT Score: -91.20

Only new treatment for DMD

Recs

0
Member Avatar NHWeston102 (62.99) Submitted: 2/1/2013 10:27:17 AM : Outperform Start Price: $27.48 SRPT Score: -87.33

Fast track approval, followed by pruce spike, followed by a big pharma buy out!! A good company that has done a good thing and deserves all the best - as do its buyers.

Recs

0
Member Avatar BioPharmacist (< 20) Submitted: 12/12/2012 1:47:23 AM : Outperform Start Price: $25.98 SRPT Score: -90.86

Will receive the first ever FDA breakthrough designation for their lead drug.

Results 1 - 20 of 55 : 1 2 3 Next »

Featured Broker Partners


Advertisement